The role of tumor-associated macrophages in tumor vascularization

Vascular Cell

Volumn 5, Issue 1, 2013, Pages

  Guo, Chunqing ^a   Buranych, Annicole ^a   Sarkar, Devanand ^a,b   Fisher, Paul B ^a,b   Wang, Xiang Yang ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Angiogenesis; Tumor vascularization; Tumor associated macrophages

Indexed keywords

EID: 84889027175     PISSN: None     EISSN: 2045824X     Source Type: Journal    
DOI: 10.1186/2045-824X-5-20     Document Type: Article

References (154)

1. Tumorigenesis and the angiogenic switch. Bergers G, Benjamin LE, Nat Rev Cancer 2003 3 401 410 10.1038/nrc1093 12778130 (Pubitemid 37328844)
2. The hallmarks of cancer. Hanahan D, Weinberg RA, Cell 2000 100 57 70 10.1016/S0092-8674(00)81683-9 10647931 (Pubitemid 30046295)
3. Angiogenesis in health and disease. Carmeliet P, Nat Med 2003 9 653 660 10.1038/nm0603-653 12778163 (Pubitemid 36749213)
4. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Hanahan D, Folkman J, Cell 1996 86 353 364 10.1016/S0092-8674(00) 80108-7 8756718 (Pubitemid 26272076)
5. Macrophage diversity enhances tumor progression and metastasis. Qian BZ, Pollard JW, Cell 2010 141 39 51 10.1016/j.cell.2010.03.014 20371344
6. Trophic macrophages in development and disease. Pollard JW, Nat Rev Immunol 2009 9 259 270 10.1038/nri2528 19282852
7. Alternative activation of macrophages: mechanism and functions. Gordon S, Martinez FO, Immunity 2010 32 593 604 10.1016/j.immuni.2010.05.007 20510870
8. Protective and pathogenic functions of macrophage subsets. Murray PJ, Wynn TA, Nat Rev Immunol 2011 11 723 737 10.1038/nri3073 21997792
9. Paradoxical roles of the immune system during cancer development. de Visser KE, Eichten A, Coussens LM, Nat Rev Cancer 2006 6 24 37 10.1038/nrc1782 16397525 (Pubitemid 43053650)
10. Inflammation and cancer. Coussens LM, Werb Z, Nature 2002 420 860 867 10.1038/nature01322 12490959 (Pubitemid 36019639)
11. Cancer-related inflammation. Mantovani A, Allavena P, Sica A, Balkwill F, Nature 2008 454 436 444 10.1038/nature07205 18650914
12. The role of myeloid cells in the promotion of tumour angiogenesis. Murdoch C, Muthana M, Coffelt SB, Lewis CE, Nat Rev Cancer 2008 8 618 631 10.1038/nrc2444 18633355
13. The angiogenic switch in carcinogenesis. Baeriswyl V, Christofori G, Seminars Cancer Biol 2009 19 329 337 10.1016/j.semcancer.2009.05.003
14. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Condeelis J, Pollard JW, Cell 2006 124 263 266 10.1016/j.cell.2006. 01.007 16439202 (Pubitemid 43121975)
15. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Politi LS, Gentner B, Brown JL, Naldini L, De Palma M, Cancer Cell 2011 19 512 526 10.1016/j.ccr.2011.02.005 21481792
16. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, Mack M, Pipeleers D, In't Veld P, De Baetselier P, Van Ginderachter JA, Cancer Res 2010 70 5728 5739 10.1158/0008-5472.CAN-09-4672 20570887
17. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Pucci F, Venneri MA, Biziato D, Nonis A, Moi D, Sica A, Di Serio C, Naldini L, De Palma M, Blood 2009 114 901 914 10.1182/blood-2009-01-200931 19383967
18. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Mantovani A, Allavena P, Sica A, Eur J Cancer 2004 40 1660 1667 10.1016/j.ejca.2004.03.016 15251154 (Pubitemid 38902900)
19. Distinct role of macrophages in different tumor microenvironments. Lewis CE, Pollard JW, Cancer Res 2006 66 605 612 10.1158/0008-5472.CAN-05-4005 16423985 (Pubitemid 43165918)
20. Macrophage polarization in tumour progression. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A, Seminars Cancer Biol 2008 18 349 355 10.1016/j.semcancer.2008.03.004
21. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A, Trends Immunol 2002 23 549 555 10.1016/S1471-4906(02)02302-5 12401408 (Pubitemid 35223554)
22. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, et al. Blood 2006 107 2112 2122 10.1182/blood-2005-01-0428 16269622 (Pubitemid 43289397)
23. Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Hagemann T, Biswas SK, Lawrence T, Sica A, Lewis CE, Blood 2009 113 3139 3146 10.1182/blood-2008-12-172825 19171876
24. Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. Ojalvo LS, Whittaker CA, Condeelis JS, Pollard JW, J Immunol 2010 184 702 712 10.4049/jimmunol.0902360 20018620
25. Dual role of macrophages in tumor growth and angiogenesis. Lamagna C, Aurrand-Lions M, Imhof BA, J Leukoc Biol 2006 80 705 713 10.1189/jlb.1105656 16864600 (Pubitemid 44835885)
26. miR-511-3p modulates genetic programs of tumor-associated macrophages. Squadrito ML, Pucci F, Magri L, Moi D, Gilfillan GD, Ranghetti A, Casazza A, Mazzone M, Lyle R, Naldini L, De Palma M, Cell Rep 2012 1 141 154 10.1016/j.celrep.2011.12.005 22832163
27. Leukocyte composition of human breast cancer. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM, Proc Natl Acad Sci U S A 2012 109 2796 2801 10.1073/pnas.1104303108 21825174
28. Identification and manipulation of tumor associated macrophages in human cancers. Heusinkveld M, van der Burg SH, J Translational Med 2011 9 216 10.1186/1479-5876-9-216
29. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. Bingle L, Brown NJ, Lewis CE, J Pathol 2002 196 254 265 10.1002/path.1027 11857487 (Pubitemid 34189413)
30. Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment. Clear AJ, Lee AM, Calaminici M, Ramsay AG, Morris KJ, Hallam S, Kelly G, Macdougall F, Lister TA, Gribben JG, Blood 2010 115 5053 5056 10.1182/blood-2009-11-253260 20375314
31. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL, Cancer Res 1996 56 4625 4629 8840975 (Pubitemid 26338061)
32. Role of macrophage polarization in tumor angiogenesis and vessel normalization: implications for new anticancer therapies. Chen P, Bonaldo P, Int Rev Cell Mol Biol 2013 301 1 35 23317816
33. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Hasita H, Komohara Y, Okabe H, Masuda T, Ohnishi K, Lei XF, Beppu T, Baba H, Takeya M, Cancer Sci 2010 101 1913 1919 10.1111/j.1349-7006.2010.01614.x 20545696
34. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Nishie A, Ono M, Shono T, Fukushi J, Otsubo M, Onoue H, Ito Y, Inamura T, Ikezaki K, Fukui M, et al. Clin Cancer Res 1999 5 1107 1113 10353745 (Pubitemid 29233226)
35. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW, Nature 2011 475 222 225 10.1038/nature10138 21654748
36. Differential macrophage programming in the tumor microenvironment. Ruffell B, Affara NI, Coussens LM, Trends Immunol 2012 33 119 126 10.1016/j.it.2011.12.001 22277903
37. Macrophage regulation of tumor angiogenesis: implications for cancer therapy. Squadrito ML, De Palma M, Mol Aspects Med 2011 32 123 145 10.1016/j.mam.2011.04.005 21565215
38. "Re-educating" tumor-associated macrophages by targeting NF-kappaB. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR, J Experiment Med 2008 205 1261 1268 10.1084/jem.20080108 (Pubitemid 351831483)
39. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Wang YC, He F, Feng F, Liu XW, Dong GY, Qin HY, Hu XB, Zheng MH, Liang L, Feng L, et al. Cancer Res 2010 70 4840 4849 10.1158/0008-5472.CAN-10-0269 20501839
40. Wnt5a induces a tolerogenic phenotype of macrophages in sepsis and breast cancer patients. Bergenfelz C, Medrek C, Ekstrom E, Jirstrom K, Janols H, Wullt M, Bredberg A, Leandersson K, J Immunol 2012 188 5448 5458 10.4049/jimmunol. 1103378 22547701
41. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, et al. Cell metabolism 2007 6 137 143 10.1016/j.cmet.2007.06.010 17681149 (Pubitemid 47189091)
42. Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Pello OM, De Pizzol M, Mirolo M, Soucek L, Zammataro L, Amabile A, Doni A, Nebuloni M, Swigart LB, Evan GI, et al. Blood 2012 119 411 421 10.1182/blood-2011-02-339911 22067385
43. Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor. Yaddanapudi K, Putty K, Rendon BE, Lamont GJ, Faughn JD, Satoskar A, Lasnik A, Eaton JW, Mitchell RA, J Immunol 2013 190 2984 2993 10.4049/jimmunol.1201650 23390297
44. Corrupt policemen: inflammatory cells promote tumor angiogenesis. Zumsteg A, Christofori G, Curr Opin Oncol 2009 21 60 70 10.1097/CCO.0b013e32831bed7e 19125020
45. Cellular events associated with inflammatory angiogenesis in the mouse cornea. Sunderkotter C, Beil W, Roth J, Sorg C, Am J Pathol 1991 138 931 939 1707239
46. Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Onita T, Ji PG, Xuan JW, Sakai H, Kanetake H, Maxwell PH, Fong GH, Gabril MY, Moussa M, Chin JL, Clin Cancer Res 2002 8 471 480 11839666 (Pubitemid 34193967)
47. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. Lin EY, Nguyen AV, Russell RG, Pollard JW, J Exp Med 2001 193 727 740 10.1084/jem.193.6.727 11257139 (Pubitemid 32524466)
48. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW, Cancer Res 2006 66 11238 11246 10.1158/0008-5472.CAN-06-1278 17114237 (Pubitemid 46009952)
49. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Zhang W, Zhu XD, Sun HC, Xiong YQ, Zhuang PY, Xu HX, Kong LQ, Wang L, Wu WZ, Tang ZY, Clin Cancer Res 2010 16 3420 3430 10.1158/1078-0432.CCR-09-2904 20570927
50. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Ojalvo LS, King W, Cox D, Pollard JW, Am J Pathol 2009 174 1048 1064 10.2353/ajpath.2009.080676 19218341
51. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. Lewis JS, Landers RJ, Underwood JC, Harris AL, Lewis CE, J Pathol 2000 192 150 158 10.1002/1096-9896(2000)9999:9999<::AID-PATH687>3.0.CO;2-G 11004690
52. Tumor-associated macrophages press the angiogenic switch in breast cancer. Lin EY, Pollard JW, Cancer Res 2007 67 5064 5066 10.1158/0008-5472.CAN- 07-0912 17545580 (Pubitemid 46997238)
53. Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Lin EY, Li JF, Bricard G, Wang W, Deng Y, Sellers R, Porcelli SA, Pollard JW, Mol Oncol 2007 1 288 302 10.1016/j.molonc.2007.10.003 18509509 (Pubitemid 350181649)
54. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, Cheresh DA, Johnson RS, Nature 2008 456 814 818 10.1038/nature07445 18997773
55. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, et al. Cancer Discovery 2011 1 54 67 10.1158/2159-8274.CD-10-0028 22039576
56. Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. Chatterjee S, Heukamp LC, Siobal M, Schottle J, Wieczorek C, Peifer M, Frasca D, Koker M, Konig K, Meder L, et al. J Clin Invest 2013 123 1732 1740 10.1172/JCI65385 23454747
57. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. Dirkx AE, Oude Egbrink MG, Wagstaff J, Griffioen AW, J Leukoc Biol 2006 80 1183 1196 10.1189/jlb.0905495 16997855 (Pubitemid 44904956)
58. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, et al. Cell 2007 131 463 475 10.1016/j.cell.2007.08.038 17981115 (Pubitemid 350007692)
59. Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2. Brecht K, Weigert A, Hu J, Popp R, Fisslthaler B, Korff T, Fleming I, Geisslinger G, Brune B, FASEB J 2011 25 2408 2417 10.1096/fj.10-179473 21450910
60. Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner. Chen P, Huang Y, Bong R, Ding Y, Song N, Wang X, Song X, Luo Y, Clin Ca Res 2011 17 7230 7239 10.1158/1078-0432.CCR-11-1354
61. Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via alpha9beta1 integrin. Kale S, Raja R, Thorat D, Soundararajan G, Patil TV, Kundu GC, Oncogene 2013 in press
62. Proteolytic networks in cancer. Mason SD, Joyce JA, Trends Cell Biol 2011 21 228 237 10.1016/j.tcb.2010.12.002 21232958
63. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, Berman T, Joyce JA, Genes Dev 2010 24 241 255 10.1101/gad.1874010 20080943
64. Cathepsin S from both tumor and tumor-associated cells promote cancer growth and neovascularization. Small DM, Burden RE, Jaworski J, Hegarty SM, Spence S, Burrows JF, McFarlane C, Kissenpfennig A, McCarthy HO, Johnston JA, et al. Int J Cancer 2013 133 2102 2112 10.1002/ijc.28238 23629809
65. The extracellular matrix: a dynamic niche in cancer progression. Lu P, Weaver VM, Werb Z, J Cell Biol 2012 196 395 406 10.1083/jcb.201102147 22351925
66. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D, Nat Cell Biol 2000 2 737 744 10.1038/35036374 11025665
67. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Coussens LM, Tinkle CL, Hanahan D, Werb Z, Cell 2000 103 481 490 10.1016/S0092-8674(00)00139-2 11081634
68. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. Giraudo E, Inoue M, Hanahan D, J Clin Invest 2004 114 623 633 10.1172/JCI200422087 15343380 (Pubitemid 39578752)
69. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Ahn GO, Brown JM, Cancer cell 2008 13 193 205 10.1016/j.ccr.2007.11.032 18328424 (Pubitemid 351318369)
70. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, Song H, Vandenberg S, Johnson RS, Werb Z, Bergers G, Cancer Cell 2008 13 206 220 10.1016/j.ccr.2008.01.034 18328425 (Pubitemid 351318372)
71. Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast. Engels K, Fox SB, Whitehouse RM, Gatter KC, Harris AL, J Pathol 1997 182 414 420 10.1002/(SICI)1096-9896(199708)182:4<414::AID-PATH897>3.0.CO;2-Q 9306962 (Pubitemid 27317206)
72. Interferon gamma-dependent induction of thymidine phosphorylase/platelet- derived endothelial growth factor through gamma-activated sequence-like element in human macrophages. Goto H, Kohno K, Sone S, Akiyama S, Kuwano M, Ono M, Cancer Res 2001 61 469 473 11212233 (Pubitemid 32128599)
73. Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. Hotchkiss KA, Ashton AW, Klein RS, Lenzi ML, Zhu GH, Schwartz EL, Cancer Res 2003 63 527 533 12543812 (Pubitemid 36152517)
74. Infiltration of thymidine phosphorylase-positive macrophages is closely associated with tumor angiogenesis and survival in intestinal type gastric cancer. Kawahara A, Hattori S, Akiba J, Nakashima K, Taira T, Watari K, Hosoi F, Uba M, Basaki Y, Koufuji K, et al. Oncology reports 2010 24 405 415 20596627
75. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Aharinejad S, Paulus P, Sioud M, Hofmann M, Zins K, Schafer R, Stanley ER, Abraham D, Cancer Res 2004 64 5378 5384 10.1158/0008-5472.CAN-04-0961 15289345 (Pubitemid 39006559)
76. Vascular endothelial growth factor receptor-1 signaling promotes mobilization of macrophage lineage cells from bone marrow and stimulates solid tumor growth. Muramatsu M, Yamamoto S, Osawa T, Shibuya M, Cancer Res 2010 70 8211 8221 10.1158/0008-5472.CAN-10-0202 20924106
77. Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages. Linde N, Lederle W, Depner S, van Rooijen N, Gutschalk CM, Mueller MM, J Pathol 2012 227 17 28 10.1002/path.3989 22262122
78. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Serbina NV, Pamer EG, Nat Immunol 2006 7 311 317 16462739
79. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, Toi M, Cancer 2001 92 1085 1091 10.1002/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K 11571719 (Pubitemid 32861655)
80. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K, Clin Cancer Res 2000 6 3282 3289 10955814 (Pubitemid 30637758)
81. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Murdoch C, Giannoudis A, Lewis CE, Blood 2004 104 2224 2234 10.1182/blood-2004-03-1109 15231578 (Pubitemid 39331817)
82. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. Zhang J, Lu Y, Pienta KJ, J Natl Cancer Inst 2010 102 522 528 10.1093/jnci/djq044 20233997
83. CCL2 and interleukin-6 promote survival of human CD11b + peripheral blood mononuclear cells and induce M2-type macrophage polarization. Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ, J Biologic Chem 2009 284 34342 34354 10.1074/jbc.M109.042671
84. Cancer and the chemokine network. Balkwill F, Nat Rev Cancer 2004 4 540 550 10.1038/nrc1388 15229479 (Pubitemid 38868623)
85. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC, Nat Med 2004 10 858 864 10.1038/nm1075 15235597 (Pubitemid 39070860)
86. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, Di Serio C, Naldini L, De Palma M, Tozer GM, Lewis CE, J Clin Invest 2011 121 1969 1973 10.1172/JCI44562 21490397
87. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM, J Clin Invest 2010 120 694 705 10.1172/JCI40283 20179352
88. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG, Cancer research 2010 70 5679 5685 10.1158/0008-5472.CAN-09- 4446 20631066
89. The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Sanchez-Martin L, Estecha A, Samaniego R, Sanchez-Ramon S, Vega MA, Sanchez-Mateos P, Blood 2011 117 88 97 10.1182/blood-2009-12-258186 20930067
90. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Fischer C, Mazzone M, Jonckx B, Carmeliet P, Nat Rev Cancer 2008 8 942 956 10.1038/nrc2524 19029957
91. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, Loges S, Albrecht I, Jonckx B, Vinckier S, et al. Cell 2010 141 178 190 10.1016/j.cell.2010.02.039 20371353
92. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, et al. Cancer Cell 2011 19 31 44 10.1016/j.ccr.2010.11.009 21215706
93. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H, J Clin Invest 2008 118 3367 3377 10.1172/JCI35213 18776941
94. Importance of direct macrophage-tumor cell interaction on progression of human glioma. Komohara Y, Horlad H, Ohnishi K, Fujiwara Y, Bai B, Nakagawa T, Suzu S, Nakamura H, Kuratsu J, Takeya M, Cancer Sci 2012 103 2165 2172 10.1111/cas.12015 22957741
95. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Xin H, Herrmann A, Reckamp K, Zhang W, Pal S, Hedvat M, Zhang C, Liang W, Scuto A, Weng S, et al. Cancer Res 2011 71 6601 6610 10.1158/0008-5472.CAN-11-1217 21920898
96. The Ets2 transcription factor inhibits apoptosis induced by colony-stimulating factor 1 deprivation of macrophages through a Bcl-xL-dependent mechanism. Sevilla L, Aperlo C, Dulic V, Chambard JC, Boutonnet C, Pasquier O, Pognonec P, Boulukos KE, Mol Cell Biol 1999 19 2624 2634 10082528 (Pubitemid 29144506)
97. Activated Ets2 is required for persistent inflammatory responses in the motheaten viable model. Wei G, Guo J, Doseff AI, Kusewitt DF, Man AK, Oshima RG, Ostrowski MC, J Immunol 2004 173 1374 1379 15240733 (Pubitemid 38924318)
98. An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis. Zabuawala T, Taffany DA, Sharma SM, Merchant A, Adair B, Srinivasan R, Rosol TJ, Fernandez S, Huang K, Leone G, Ostrowski MC, Cancer Res 2010 70 1323 1333 10.1158/0008-5472.CAN-09-1474 20145133
99. Tumor-associated macrophages promote angiogenesis and lymphangiogenesis of gastric cancer. Wu H, Xu JB, He YL, Peng JJ, Zhang XH, Chen CQ, Li W, Cai SR, J Surg Oncol 2012 106 462 468 10.1002/jso.23110 22488237
100. Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway. Chen W, Ma T, Shen XN, Xia XF, Xu GD, Bai XL, Liang TB, Cancer Res 2012 72 1363 1372 10.1158/0008-5472.CAN-11-2684 22287548
101. Flt-1 signaling in macrophages promotes glioma growth in vivo. Kerber M, Reiss Y, Wickersheim A, Jugold M, Kiessling F, Heil M, Tchaikovski V, Waltenberger J, Shibuya M, Plate KH, Machein MR, Cancer Res 2008 68 7342 7351 10.1158/0008-5472.CAN-07-6241 18794121
102. HIFs, angiogenesis, and cancer. Yang Y, Sun M, Wang L, Jiao B, J Cell Biochem 2013 114 967 974 10.1002/jcb.24438 23225225
103. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Chan DA, Kawahara TL, Sutphin PD, Chang HY, Chi JT, Giaccia AJ, Cancer Cell 2009 15 527 538 10.1016/j.ccr.2009.04.010 19477431
104. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Lewis C, Murdoch C, Am J Pathol 2005 167 627 635 10.1016/S0002-9440(10)62038-X 16127144 (Pubitemid 41216349)
105. Vasohibin-1 and vasohibin-2 expression in gastric cancer cells and TAMs. Shen Z, Kauttu T, Seppanen H, Vainionpaa S, Ye Y, Wang S, Mustonen H, Puolakkainen P, Med Oncol 2012 29 2718 2726 10.1007/s12032-012-0212-1 22438034
106. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, et al. Oncogene 2005 24 5552 5560 10.1038/sj.onc.1208719 16007214 (Pubitemid 43119350)
107. Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. Niu G, Briggs J, Deng J, Ma Y, Lee H, Kortylewski M, Kujawski M, Kay H, Cress WD, Jove R, Yu H, Mol Cancer Res 2008 6 1099 1105 10.1158/1541-7786.MCR-07-2177 18644974
108. eIF2{alpha} Kinase PKR modulates the hypoxic response by Stat3-dependent transcriptional suppression of HIF-1{alpha}. Papadakis AI, Paraskeva E, Peidis P, Muaddi H, Li S, Raptis L, Pantopoulos K, Simos G, Koromilas AE, Cancer Res 2010 70 7820 7829 10.1158/0008-5472.CAN-10-0215 20924113
109. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. Jung JE, Lee HG, Cho IH, Chung DH, Yoon SH, Yang YM, Lee JW, Choi S, Park JW, Ye SK, Chung MH, FASEB J 2005 19 1296 1298 15919761 (Pubitemid 41113728)
110. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Lang SA, Moser C, Gaumann A, Klein D, Glockzin G, Popp FC, Dahlke MH, Piso P, Schlitt HJ, Geissler EK, Stoeltzing O, Clin Cancer Res 2007 13 6459 6468 10.1158/1078-0432.CCR-07-1104 17975158 (Pubitemid 350075036)
111. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, et al. Clin Cancer Res 2011 17 2538 2548 10.1158/1078-0432.CCR-10-3314 21343371
112. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. De Palma M, Venneri MA, Roca C, Naldini L, Nat Med 2003 9 789 795 10.1038/nm871 12740570 (Pubitemid 36749231)
113. Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses. Geissmann F, Auffray C, Palframan R, Wirrig C, Ciocca A, Campisi L, Narni-Mancinelli E, Lauvau G, Immunol Cell Biol 2008 86 398 408 10.1038/icb.2008.19 18392044 (Pubitemid 351948210)
114. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. MacDonald KP, Palmer JS, Cronau S, Seppanen E, Olver S, Raffelt NC, Kuns R, Pettit AR, Clouston A, Wainwright B, et al. Blood 2010 116 3955 3963 10.1182/blood-2010-02-266296 20682855
115. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, Naldini L, Cancer Cell 2005 8 211 226 10.1016/j.ccr.2005.08.002 16169466 (Pubitemid 41317592)
116. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, Mazzieri R, Doglioni C, Naldini L, Blood 2007 109 5276 5285 10.1182/blood-2006-10-053504 17327411 (Pubitemid 46890548)
117. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. Murdoch C, Tazzyman S, Webster S, Lewis CE, J Immunol 2007 178 7405 7411 17513791 (Pubitemid 46847468)
118. TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. Matsubara T, Kanto T, Kuroda S, Yoshio S, Higashitani K, Kakita N, Miyazaki M, Sakakibara M, Hiramatsu N, Kasahara A, et al. Hepatology 2013 57 1416 1425 10.1002/hep.25965 22815256
119. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Augustin HG, Koh GY, Thurston G, Alitalo K, Nat Rev Mol Cell Biol 2009 10 165 177 10.1038/nrm2639 19234476
120. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Coffelt SB, Tal AO, Scholz A, De Palma M, Patel S, Urbich C, Biswas SK, Murdoch C, Plate KH, Reiss Y, Lewis CE, Cancer Res 2010 70 5270 5280 10.1158/0008-5472.CAN-10-0012 20530679
121. Myeloid-derived suppressor cells as regulators of the immune system. Gabrilovich DI, Nagaraj S, Nat Rev Immunol 2009 9 162 174 10.1038/nri2506 19197294
122. Coordinated regulation of myeloid cells by tumours. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V, Nat Rev Immunol 2012 12 253 268 10.1038/nri3175 22437938
123. Expansion of myeloid immune suppressor Gr + CD11b + cells in tumor-bearing host directly promotes tumor angiogenesis. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC, Cancer Cell 2004 6 409 421 10.1016/j.ccr.2004.08.031 15488763 (Pubitemid 39361441)
124. Altered macrophage differentiation and immune dysfunction in tumor development. Sica A, Bronte V, J Clin Invest 2007 117 1155 1166 10.1172/JCI31422 17476345 (Pubitemid 46718400)
125. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. Kusmartsev S, Gabrilovich DI, J Immunol 2005 174 4880 4891 15814715
126. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. Kusmartsev S, Nagaraj S, Gabrilovich DI, J Immunol 2005 175 4583 4592 16177103 (Pubitemid 41361997)
127. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S, J Immunol 2007 179 977 983 17617589
128. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, Cho HI, Celis E, Quiceno DG, Padhya T, et al. J Exp Med 2010 207 2439 2453 10.1084/jem.20100587 20876310
129. Endothelial cells provide an instructive niche for the differentiation and functional polarization of M2-like macrophages. He H, Xu J, Warren CM, Duan D, Li X, Wu L, Iruela-Arispe ML, Blood 2012 120 3152 3162 10.1182/blood-2012-04- 422758 22919031
130. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Carmeliet P, Jain RK, Nat Rev Drug Dis 2011 10 417 427 10.1038/nrd3455
131. Modes of resistance to anti-angiogenic therapy. Bergers G, Hanahan D, Nat Rev Cancer 2008 8 592 603 10.1038/nrc2442 18650835
132. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, Blanchard D, Bais C, Peale FV, van Bruggen N, et al. Nature 2007 450 825 831 10.1038/nature06348 18064003 (Pubitemid 350231321)
133. Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Shojaei F, Ferrara N, Cancer Res 2008 68 5501 5504 10.1158/0008-5472.CAN-08-0925 18632597
134. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, Schwendener RA, Br J Cancer 2006 95 272 281 10.1038/sj.bjc.6603240 16832418 (Pubitemid 44187587)
135. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, Johnson M, Lusis AJ, Cohen DA, Iruela-Arispe ML, Wu L, Blood 2010 115 1461 1471 10.1182/blood-2009- 08-237412 20008303
136. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Paulus P, Stanley ER, Schafer R, Abraham D, Aharinejad S, Cancer Res 2006 66 4349 4356 10.1158/0008-5472.CAN-05-3523 16618760
137. Role of macrophage targeting in the antitumor activity of trabectedin. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, et al. Cancer cell 2013 23 249 262 10.1016/j.ccr.2013.01.008 23410977
138. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R, Science 2003 300 1155 1159 10.1126/science.1082504 12750523 (Pubitemid 36583102)
139. The tumor-immune microenvironment and response to radiation therapy. Shiao SL, Coussens LM, J Mammary Gland Biol Neoplasia 2010 15 411 421 10.1007/s10911-010-9194-9 21161342
140. Macrophage content of murine sarcomas and carcinomas: associations with tumor growth parameters and tumor radiocurability. Milas L, Wike J, Hunter N, Volpe J, Basic I, Cancer Res 1987 47 1069 1075 3802091 (Pubitemid 17027931)
141. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A, Brown JM, Proc Natl Acad Sci U S A 2010 107 8363 8368 10.1073/pnas.0911378107 20404138
142. Irradiation promotes an m2 macrophage phenotype in tumor hypoxia. Chiang CS, Fu SY, Wang SC, Yu CF, Chen FH, Lin CM, Hong JH, Front Oncol 2012 2 89 22888475
143. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Xu J, Escamilla J, Mok S, David J, Priceman S, West B, Bollag G, McBride W, Wu L, Cancer Res 2013 73 2782 2794 10.1158/0008-5472.CAN-12-3981 23418320
144. Cancer: Macrophages limit chemotherapy. De Palma M, Lewis CE, Nature 2011 472 303 304 10.1038/472303a 21512566
145. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Szlosarek PW, Balkwill FR, Lancet Oncol 2003 4 565 573 10.1016/S1470-2045(03)01196-3 12965278 (Pubitemid 38351714)
146. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Pluddemann A, Charles K, Gordon S, Balkwill FR, J Immunol 2006 176 5023 5032 16585599
147. Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis. Sangaletti S, Tripodo C, Ratti C, Piconese S, Porcasi R, Salcedo R, Trinchieri G, Colombo MP, Chiodoni C, Cancer Res 2010 70 7764 7775 10.1158/0008-5472.CAN- 10-0471 20924115
148. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. De Palma M, Mazzieri R, Politi LS, Pucci F, Zonari E, Sitia G, Mazzoleni S, Moi D, Venneri MA, Indraccolo S, et al. Cancer Cell 2008 14 299 311 10.1016/j.ccr.2008.09.004 18835032
149. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S, Korets L, Lam J, Tawfik D, DeNardo DG, et al. Cancer Cell 2010 17 121 134 10.1016/j.ccr.2009.12.019 20138013
150. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Jain RK, Science 2005 307 58 62 10.1126/science.1104819 15637262 (Pubitemid 40093472)
151. Targeting vessel abnormalization in cancer. Garber K, J Natl Cancer Inst 2007 99 991 995 10.1093/jnci/djm056 17596567
152. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. De Bock K, Cauwenberghs S, Carmeliet P, Curr Opin Genet Dev 2011 21 73 79 10.1016/j.gde.2010.10.008 21106363
153. Macrophage regulation of tumor angiogenesis: Implications for cancer therapy. Squadrito ML, De Palma MD, Mol Aspects Med 2011 32 123 145 10.1016/j.mam.2011.04.005 21565215
154. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, et al. Science 2011 331 1612 1616 10.1126/science.1198443 21436454